🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to researchers.

A Global Challenge

Gonorrhoea infections are on the rise globally, with estimates suggesting in excess of 82 million instances annually. Notably increased rates are seen in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the context of growing infection rates, the spread of superbugs and the very limited therapeutic options at this time.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in December for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in the same week. This drug, which is employed against urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to results published in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which uses an injection and a pill. The study enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the authority to license and sell the drug in many regions with limited resources.

Medical professionals treating patients have expressed positive views. Having a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is considered crucial to reduce the burden of the disease for people and to prevent the spread of untreatable gonorrhoea worldwide.